دورية أكاديمية
أعرض في EDS

Assessing depression recurrence, cognitive burden, and neurobiological homeostasis in late life: Design and rationale of the REMBRANDT Study.

التفاصيل البيبلوغرافية
العنوان: Assessing depression recurrence, cognitive burden, and neurobiological homeostasis in late life: Design and rationale of the REMBRANDT Study.
المؤلفون: Taylor WD; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Science, Vanderbilt University Medical Center, Nashville, TN.; Geriatric Research, Education, and Clinical Center, Veterans Affairs Tennessee Valley Health System, Nashville, TN., Ajilore O; Department of Psychiatry, University of Illinois-Chicago, Chicago, IL., Karim HT; Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA., Butters MA; Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA., Krafty R; Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA., Boyd BD; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Science, Vanderbilt University Medical Center, Nashville, TN., Banihashemi L; Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA., Szymkowicz SM; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Science, Vanderbilt University Medical Center, Nashville, TN., Ryan C; Center for Cognitive Medicine, Department of Psychiatry and Behavioral Science, Vanderbilt University Medical Center, Nashville, TN., Hassenstab J; Departments of Neurology and Psychiatry, Washington University in St. Louis, St. Louis, MO., Landman BA; Departments of Computer Science, Electrical Engineering, and Biomedical Engineering, Vanderbilt University; Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center., Andreescu C; Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA.
المصدر: Journal of mood and anxiety disorders [J Mood Anxiety Disord] 2024 Mar; Vol. 5. Date of Electronic Publication: 2023 Nov 04.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9918646056406676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2950-0044 (Electronic) Linking ISSN: 29500044 NLM ISO Abbreviation: J Mood Anxiety Disord Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [New York] : Elsevier Inc., [2023]-.
مستخلص: Background: Late-life depression is characterized by disability, cognitive impairment and decline, and a high risk of recurrence following remission. Aside from past psychiatric history, prognostic neurobiological and clinical factors influencing recurrence risk are unclear. Moreover, it is unclear if cognitive impairment predisposes to recurrence, or whether recurrent episodes may accelerate brain aging and cognitive decline. The purpose of the REMBRANDT study (Recurrence markers, cognitive burden, and neurobiological homeostasis in late-life depression) is to better elucidate these relationships and identify phenotypic, cognitive, environmental, and neurobiological factors contributing to and predictive of depression recurrence.
Methods: Across three sites, REMBRANDT will enroll 300 depressed elders who will receive antidepressant treatment. The goal is to enroll 210 remitted depressed participants and 75 participants with no mental health history into a two-year longitudinal phase focusing on depression recurrence. Participants are evaluated every 2 months with deeper assessments occurring every 8 months, including structural and functional neuroimaging, environmental stress assessments, deep symptom phenotyping, and two weeks of 'burst' ecological momentary assessments to elucidate variability in symptoms and cognitive performance. A broad neuropsychological test battery is completed at the beginning and end of the longitudinal study.
Significance: REMBRANDT will improve our understanding of how alterations in neural circuits and cognition that persist during remission contribute to depression recurrence vulnerability. It will also elucidate how these processes may contribute to cognitive impairment and decline. This project will obtain deep phenotypic data that will help identify vulnerability and resilience factors that can help stratify individual clinical risk.
Competing Interests: CONFLICT OF INTERESTS: All authors deny any conflict of interest with this work.
References: Neuropsychopharmacology. 2009 Mar;34(4):923-31. (PMID: 18496519)
Int Psychogeriatr. 2023 Apr;35(4):193-205. (PMID: 35766159)
J Psychiatr Res. 2016 Apr;75:116-23. (PMID: 26851494)
Neuroimage. 2021 Feb 1;226:117549. (PMID: 33248255)
Annu Rev Med. 2011;62:431-45. (PMID: 20707675)
J Biomed Inform. 2009 Apr;42(2):377-81. (PMID: 18929686)
Hypertension. 2009 May;53(5):819-25. (PMID: 19273741)
Arch Gen Psychiatry. 2002 Jul;59(7):605-11. (PMID: 12090813)
Arch Gen Psychiatry. 1987 Jun;44(6):540-8. (PMID: 3579500)
J Am Geriatr Soc. 2014 Jul;62(7):1347-52. (PMID: 24890517)
Lancet. 2015 Dec 12;386(10011):2404-12. (PMID: 26423182)
Arch Gen Psychiatry. 2004 Jun;61(6):587-95. (PMID: 15184238)
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. (PMID: 9881538)
Br J Psychiatry. 2007 Apr;190:344-9. (PMID: 17401042)
Arch Gen Psychiatry. 2007 Jul;64(7):810-8. (PMID: 17606815)
Alzheimers Dement. 2011 Nov;7(6):593-601. (PMID: 22055976)
Int Psychogeriatr. 2023 Dec;35(12):689-691. (PMID: 36815301)
Psychopharmacol Bull. 2002 Spring;36(2):58-68. (PMID: 12397841)
Behav Res Ther. 1990;28(6):487-95. (PMID: 2076086)
Mol Psychiatry. 2022 Jan;27(1):180-191. (PMID: 34404915)
J Intern Med. 2004 Sep;256(3):183-94. (PMID: 15324362)
Br J Psychiatry. 2013 May;202(5):329-35. (PMID: 23637108)
Alzheimers Dement. 2011 May;7(3):270-9. (PMID: 21514249)
JAMA. 1999 Jan 6;281(1):39-45. (PMID: 9892449)
Dev Cogn Neurosci. 2018 Aug;32:43-54. (PMID: 29567376)
BMJ Open Sport Exerc Med. 2017 Sep 13;3(1):e000254. (PMID: 29018543)
Psychiatry Res. 1986 Jul;18(3):227-37. (PMID: 3749384)
J Clin Epidemiol. 2016 May;73:119-27. (PMID: 26931289)
Depress Anxiety. 2018 Jul;35(7):658-667. (PMID: 29749006)
Am J Psychiatry. 2000 Dec;157(12):1949-54. (PMID: 11097959)
J Clin Psychopharmacol. 1990 Apr;10(2):96-104. (PMID: 2341598)
Arch Neurol. 1989 Oct;46(10):1121-3. (PMID: 2803071)
JAMA Neurol. 2014 Aug;71(8):961-70. (PMID: 24886908)
Front Digit Health. 2022 Apr 29;4:880055. (PMID: 35574256)
Psychol Med. 2010 Jan;40(1):41-50. (PMID: 19460188)
J Clin Epidemiol. 1993 Oct;46(10):1129-40. (PMID: 8410098)
Psychiatry Res. 1992 Mar;41(3):237-48. (PMID: 1594710)
Br J Psychiatry. 2007 Sep;191:218-23. (PMID: 17766761)
Psychiatry Res. 1997 Oct 10;72(3):149-59. (PMID: 9406904)
J Health Soc Behav. 1983 Dec;24(4):385-96. (PMID: 6668417)
J Clin Psychiatry. 2003;64 Suppl 15:13-7. (PMID: 14658986)
Neuroscience. 2013 Oct 10;250:733-42. (PMID: 23891965)
J Psychiatr Res. 2013 Jun;47(6):829-34. (PMID: 23478048)
J Am Geriatr Soc. 2018 Apr;66 Suppl 1:S17-S23. (PMID: 29659005)
J Gerontol A Biol Sci Med Sci. 2022 May 5;77(5):1055-1062. (PMID: 34758065)
JAMA Psychiatry. 2022 Oct 1;79(10):1023-1031. (PMID: 36044201)
J Abnorm Psychol. 1993 Feb;102(1):20-8. (PMID: 8436695)
J Affect Disord. 1998 Sep;50(2-3):97-108. (PMID: 9858069)
Br J Psychiatry. 1979 Apr;134:382-9. (PMID: 444788)
Transl Psychiatry. 2023 May 10;13(1):160. (PMID: 37160884)
J Aging Health. 2018 Jul;30(6):904-923. (PMID: 28553813)
Mol Psychiatry. 2017 Mar;22(3):450-457. (PMID: 27090303)
Transl Psychiatry. 2020 Sep 18;10(1):317. (PMID: 32948749)
Psychiatry Res. 1991 Aug;38(2):143-62. (PMID: 1754629)
Biol Psychiatry. 2015 Jul 1;78(1):67-76. (PMID: 25483401)
Neuropsychopharmacology. 2017 Dec;42(13):2583-2592. (PMID: 28361870)
Nat Rev Neurosci. 2009 Jun;10(6):434-45. (PMID: 19401723)
Am J Geriatr Psychiatry. 2019 Dec;27(12):1316-1330. (PMID: 31477459)
J Clin Epidemiol. 2016 May;73:128-34. (PMID: 26939927)
Am J Geriatr Psychiatry. 2004 Jan-Feb;12(1):22-9. (PMID: 14729555)
N Engl J Med. 2006 Mar 16;354(11):1130-8. (PMID: 16540613)
Curr Psychiatry Rep. 2007 Dec;9(6):449-59. (PMID: 18221624)
J Alzheimers Dis. 2015;45(1):175-85. (PMID: 25471193)
Soc Cogn Affect Neurosci. 2015 Apr;10(4):474-85. (PMID: 24847113)
Neurology. 2015 Sep 15;85(11):976-83. (PMID: 26291281)
J Int Neuropsychol Soc. 2023 Jun;29(5):459-471. (PMID: 36062528)
J Biomed Inform. 2019 Jul;95:103208. (PMID: 31078660)
Du Bois Rev. 2011 Spring;8(1):95-113. (PMID: 29887911)
Acta Psychiatr Scand. 2003 Feb;107(2):124-31. (PMID: 12534438)
J Psychiatr Pract. 2006 Mar;12(2):71-9. (PMID: 16728903)
Maturitas. 2018 Jun;112:85-93. (PMID: 29704922)
Br J Med Psychol. 1959;32(1):50-5. (PMID: 13638508)
Am J Geriatr Psychiatry. 2004 Jul-Aug;12(4):387-94. (PMID: 15249276)
Depress Anxiety. 2003;18(2):76-82. (PMID: 12964174)
Psychophysiology. 2012 Jul;49(7):873-84. (PMID: 22594784)
Am J Geriatr Psychiatry. 2017 Oct;25(10):1123-1134. (PMID: 28479153)
J Psychiatr Res. 2013 Nov;47(11):1686-93. (PMID: 23911057)
Psychol Med. 2012 Jun;42(6):1195-202. (PMID: 22030013)
Alzheimers Dement. 2011 May;7(3):263-9. (PMID: 21514250)
N Engl J Med. 2014 Sep 25;371(13):1228-36. (PMID: 25251617)
Arch Gen Psychiatry. 2000 Mar;57(3):285-90. (PMID: 10711915)
Hum Brain Mapp. 2012 Jul;33(7):1700-16. (PMID: 21567664)
Biol Psychiatry. 2006 Jul 1;60(1):58-65. (PMID: 16414031)
Epidemiol Psychiatr Sci. 2018 Jun;27(3):266-277. (PMID: 28183368)
Ann N Y Acad Sci. 2010 Oct;1207:155-62. (PMID: 20955439)
Br J Psychiatry. 1983 Feb;142:111-9. (PMID: 6839065)
Front Hum Neurosci. 2013 Aug 08;7:446. (PMID: 23964225)
Psychiatry Res. 2009 Apr 30;172(1):83-91. (PMID: 19452633)
معلومات مُعتمدة: UL1 TR000445 United States TR NCATS NIH HHS; R01 MH121620 United States MH NIMH NIH HHS; R01 MH121384 United States MH NIMH NIH HHS; UL1 TR002243 United States TR NCATS NIH HHS; R01 MH121619 United States MH NIMH NIH HHS
فهرسة مساهمة: Keywords: aging; cognition; depression; longitudinal design; methods; study design
تواريخ الأحداث: Date Created: 20240325 Latest Revision: 20240402
رمز التحديث: 20240402
مُعرف محوري في PubMed: PMC10959248
DOI: 10.1016/j.xjmad.2023.100038
PMID: 38523701
قاعدة البيانات: MEDLINE
الوصف
تدمد:2950-0044
DOI:10.1016/j.xjmad.2023.100038